ImpediMed Ltd
ASX:IPD
ImpediMed Ltd
Stock-Based Compensation
ImpediMed Ltd
Stock-Based Compensation Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Stock-Based Compensation | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
ImpediMed Ltd
ASX:IPD
|
Stock-Based Compensation
AU$1.6m
|
CAGR 3-Years
-19%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
-1%
|
|
|
Somnomed Ltd
ASX:SOM
|
Stock-Based Compensation
AU$1.9m
|
CAGR 3-Years
18%
|
CAGR 5-Years
36%
|
CAGR 10-Years
26%
|
|
|
C
|
Cyclopharm Ltd
ASX:CYC
|
Stock-Based Compensation
AU$383.6k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Cochlear Ltd
ASX:COH
|
Stock-Based Compensation
AU$22.4m
|
CAGR 3-Years
18%
|
CAGR 5-Years
17%
|
CAGR 10-Years
N/A
|
|
|
Austco Healthcare Ltd
ASX:AHC
|
Stock-Based Compensation
AU$310k
|
CAGR 3-Years
18%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
EMvision Medical Devices Ltd
ASX:EMV
|
Stock-Based Compensation
AU$575.1k
|
CAGR 3-Years
-33%
|
CAGR 5-Years
38%
|
CAGR 10-Years
N/A
|
|
ImpediMed Ltd
Glance View
ImpediMed Ltd. engages in the development and distribution of bioimpedance devices with a focus on medical applications in the fluid status area. The company is headquartered in Brisbane, Queensland and currently employs 73 full-time employees. The company went IPO on 2007-10-24. The firm develops various medical products that use bioimpedance spectroscopy (BIS) to measure and monitor fluid status and tissue composition. Its product includes SOZO Digital Health Platform. The company is a non-invasive BIS device delivers a snapshot of fluid status and tissue composition in approximately 30 seconds. The Company’s SOZO Applications offer clinicians deeper insights into a patient’s health. SOZO Applications include various software applications, such as L-Dex Analysis for Lymphedema, Body Composition Analysis, Segmental Analysis and HF-Dex Analysis for Heart Failure. The Company’s research devices include SFB7 and ImpediVET. SFB7 single channel, tetrapolar BIS device, which measures fluid status and tissue composition for clinical and research applications.
See Also
What is ImpediMed Ltd's Stock-Based Compensation?
Stock-Based Compensation
1.6m
AUD
Based on the financial report for Jun 30, 2025, ImpediMed Ltd's Stock-Based Compensation amounts to 1.6m AUD.
What is ImpediMed Ltd's Stock-Based Compensation growth rate?
Stock-Based Compensation CAGR 10Y
-1%
The average annual Stock-Based Compensation growth rates for ImpediMed Ltd have been -19% over the past three years , -7% over the past five years , and -1% over the past ten years .
